Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | TDO2 | P48775 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157927 | 1.00 | ADRB2 (0.56) | ADRB2PDE2AIDO1TDO2MAOA | |
| SCHEMBL56723 | 1.00 | ADRB2 (0.56) | ADRB2PDE2AIDO1TDO2MAOA | |
| Hydrochloric Acid SCHEMBL1887841 | 0.97 | ADRB2 (0.54) | ADRB2PDE2AIDO1TDO2MAOA | |
| Hydrochloric Acid SCHEMBL1002687 | 0.97 | ADRB2 (0.54) | ADRB2PDE2AIDO1TDO2MAOA | |
| Iodide SCHEMBL28918391 | 0.97 | ADRB2 (0.54) | ADRB2PDE2AIDO1TDO2MAOA | |
| Bromide SCHEMBL25231048 | 0.97 | ADRB2 (0.54) | ADRB2PDE2AIDO1TDO2MAOA | |
| Hydrochloric Acid SCHEMBL14576625 | 0.97 | ADRB2 (0.54) | ADRB2PDE2AIDO1TDO2MAOA | |
| Hydrochloric Acid SCHEMBL29227874 | 0.91 | ADRB2 (0.48) | ADRB2PDE2AIDO1TDO2MAOA | |
| Hydrochloric Acid SCHEMBL30939459 | 0.91 | ADRB2 (0.48) | ADRB2PDE2AIDO1TDO2MAOA | |
| SCHEMBL4380562 | 0.87 | SOS1 (0.46) | ADRB2PDE2AIDO1TDO2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 705 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250078176-A1 | ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS | BASF SE (DE) | 2025-03-06 | — | — | US | claimed |
| CN-118435582-A | Environmental attributes of nitrogen-containing chemicals | 巴斯夫欧洲公司 | 2024-08-02 | — | — | CN | claimed |
| CN-118184650-A | 6- (1H-pyrrolo [2,3-b ] pyridin-3-yl) quinazoline-4-amine derivative, and preparation method and application thereof | 中国人民解放军北部战区总医院 | 2024-06-14 | — | — | CN | claimed |
| WO-2023117926-A1 | ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS | BASF SE (DE) | 2023-06-29 | — | — | WO | claimed |
| CN-112430247-B | Perovskite nanocrystalline material with circular polarization luminescence and up-conversion circular polarization luminescence properties and preparation method and application thereof | 国家纳米科学中心 | 2022-12-09 | — | — | CN | claimed |
| CN-115101683-A | Chiral quasi-two-dimensional formamidine perovskite solar cell and preparation method and application thereof | 西北工业大学 | 2022-09-23 | — | — | CN | claimed |
| CN-112430247-A | Perovskite nanocrystalline material with circular polarization luminescence and up-conversion circular polarization luminescence properties and preparation method and application thereof | 国家纳米科学中心 | 2021-03-02 | — | — | CN | claimed |
| US-20180099936-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-04-12 | — | — | US | claimed |
| EP-2780324-B1 | HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-05-17 | — | — | EP | claimed |
| US-20160318871-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. | 2016-11-03 | — | — | US | claimed |
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | claimed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| US-20130116229-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2013-05-09 | — | — | US | claimed |
| US-8084630-B2 | Process for the synthesis of ramelteon and its intermediates | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-27 | — | — | US | claimed |
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-12 | — | — | US | claimed |
| EP-2098519-A1 | Process for the synthesis of ramelteon and its intermediates | Teva Pharmaceutical Industries Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | claimed |
| CN-115835909-B | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-5859008-A | Arylalkyl diazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-01-12 | — | — | US | disclosed |
| US-4988734-A | Fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1991-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | ADRB2 1490/4885PDE2A 2285/4885IDO1 4021/4885 |
| US-20160318871-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE3A, PDE5A, PDE3B | ADRB2 249/4885PDE2A 4/4885IDO1 287/4885 |
| US-20130116229-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE7A, PDE5A, PDE2A | ADRB2 591/4885PDE2A 3/4885IDO1 1702/4885 |
| US-20180099936-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE3A, PDE5A, PDE3B | ADRB2 254/4885PDE2A 4/4885IDO1 291/4885 |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | ADRB2 1661/4885PDE2A 3676/4885IDO1 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.